Hyperphosphatemia - Epidemiology Forecast to 2034

Published Date : 2025
Pages : 90
Region : United States, Japan, China, EU4 & UK

Share:

hyperphosphatemia epidemiology forecast insights

DelveInsight’s ‘Hyperphosphatemia – Epidemiology Forecast - 2034’ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China and Taiwan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China
  • Taiwan

Study Period: 2021-2034

Hyperphosphatemia Disease Understanding

Hyperphosphatemia Overview

Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. The condition may result from varying factors like an increase in phosphate intake, a decrease in phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space; the health of kidneys play a crucial role as it is the kidneys that control the amount of phosphate in the blood. Moreover, phosphate absorption can also be increased with vitamin D, leading to hyperphosphatemia through increased gut absorption of phosphate.

 

The condition is diagnosed by serum phosphate measurement with specific blood tests, which measure the levels of phosphate, calcium, magnesium, blood urea nitrogen, creatinine, vitamin D and parathyroid hormone (PTH). It is important to diagnose and find the underlying cause of hyperphosphatemia to treat and restore normal phosphate metabolism.

Hyperphosphatemia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Chronic Kidney Disease, Diagnosed Prevalent Cases of Chronic Kidney Disease, Stage-specific Distribution of Chronic Kidney Disease, Prevalent Cases of End-Stage Renal Disease, Number of ESRD Patients Undergoing Dialysis and Prevalent Cases of Hyperphosphatemia in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, China and Taiwan from 2021 to 2034.

 

Key Findings

This section provides glimpse of the Hyperphosphatemia epidemiology in the 7MM, China and Taiwan.

  • The total diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets, China and Taiwan was estimated to be 27,063,599 in 2020.
  • In the United States, the patients with Stage 3–5 CKD accounted for 2,317,671 in 2020.
  • In 2020, in the United States, the prevalence of ESRD was 797,101 and patients with ESRD on dialysis accounted for 565,941 cases.
  • The total prevalent population of hyperphosphatemia in the 7 MM, China and Taiwan is expected to increase at a CAGR of 0.42% during the forecast period 2025-2034.
  • The United States, in 2020, accounted for 481,050 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU5 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 55,631 in 2020. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 23,847 in 2020.
  • Japan, China and Taiwan in 2020, accounted for 283,831, 487,163 and 73,208 prevalent cases of hyperphosphatemia.

Country Wise- Hyperphosphatemia Epidemiology

The epidemiology segment also provides the Hyperphosphatemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China and Taiwan.

Scope of the Report

  • The report covers the descriptive overview of Hyperphosphatemia, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, China and Taiwan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Hyperphosphatemia.

Report Highlight

  • Ten Year Forecast of Hyperphosphatemia
  • 7MM, China and Taiwan Coverage
  • Delvelnsight has analysed prevalent population of Hyperphosphatemia in the 7MM, China and Taiwan which suggests that the patient pool will increase during the forecast period of 2025-2034.

Analyst Comments

  • Our forecast model has taken the chronic kidney disease prevalence of nearly 15.45% of the adult US population. Furthermore, ESRD affect 2 in every 1,000 people, and among them, 71% are on dialysis, and 29% are living with a kidney transplant. Apart from this rate, we have estimated ESRD diagnosed pool separately from the various published literature and kidney disease registries. We also analyzed various published literature and studies for the estimation of the total prevalence of CKD.
  • To estimate CKD prevalence in Germany, we have taken prevalence of 17.30% for Germany, 10% for France, 8.50% for Italy, 12.50% for Spain, 13.50% for the UK of the total adult country population. Furthermore, we have separately estimated the diagnosed ESRD patient pool based on the number of patients treated by Renal Replacement Therapy, including Dialysis and Kidney Transplantation.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Hyperphosphatemia?
  • What is the historical Hyperphosphatemia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, China and Taiwan?
  • What would be the forecasted patient pool of Hyperphosphatemia at the 7MM, China and Taiwan level?
  • What will be the growth opportunities across the 7MM, China and Taiwan with respect to the patient population pertaining to Hyperphosphatemia?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Hyperphosphatemia during the forecast period (2025-2034)?
  • At what CAGR the population is expected to grow across the 7MM, China and Taiwan during the forecast period (2025-2034)?

Reasons to buy

The Hyperphosphatemia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM, China and Taiwan Hyperphosphatemia market.
  • Quantify patient share distribution in the 7MM, China and Taiwan for Hyperphosphatemia.
  • The Hyperphosphatemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Hyperphosphatemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the ten-year forecast period using reputable sources.

Tags:

    License Type

    Offer

    Request Sample

    View Pricing

    Customize Reports As Per Your Needs

    Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

    Have a Question?

    We are happy to assist you.

    Support Person
    DelveInsight
    DelveInsight
    SUBSCRIPTION
    Platform

    Register for free trial today and gain instant access to 7000+ market
    research reports

    Latest Press Release